MedPath

Comparison of the Efficacy and Safety of Low Dose Combination Therapy and High Dose Monotherapy for the treatment of Hypertension.

Not Applicable
Conditions
Health Condition 1: null- Hypertension
Registration Number
CTRI/2013/08/003905
Lead Sponsor
Self
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
90
Inclusion Criteria

1 Hypertensive patients with uncontrolled blood pressure (Systolic BP >= 140 to 179 mmHg and/or Diastolic BP >= 90 to 109 mmHg) on low dose monotherapy with either Amlodipine (<= 5mg) or Telmisartan (<= 40 mg).

2 Age 18 to 60 years, either gender.

3 Patients who are willing to participate and sign consent document.

4 Patient willing to comply with the protocol requirements.

Exclusion Criteria

1 Secondary Hypertension.

2 Clinically evident concomitant disorder such as cardiovascular, renal, hepatic, endocrine, neurological, psychiatric or other complicating diseases or severe co-morbidities.

3 Pregnant or lactating women.

4 Female patients of childbearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study period.

5 Patients with known hypersensitivity to any of the test drug.

6 Patients with alcohol or drug dependence.

7 Patients with stage 3 hypertension (Systolic BP >= 180 mmHg and/or Diastolic BP >= 110 mmHg)

8 Patients who had any major surgery within 4 weeks of screening.

9 Any other condition that in the opinion of the Investigator that does not justify the patientâ??s participation in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in Blood Pressure Control from BaselineTimepoint: 56 Days of Study Duration
Secondary Outcome Measures
NameTimeMethod
Improvement in symptoms associated with high blood pressureTimepoint: 56 Days of Study Duration
© Copyright 2025. All Rights Reserved by MedPath